Cargando…

Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis

Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Quint, Tamara, Brunner, Patrick M., Sinz, Christoph, Steiner, Irene, Ristl, Robin, Vigl, Kornelia, Kimeswenger, Susanne, Neubauer, Katharina, Pirkhammer, Detlev, Zikeli, Martin, Hoetzenecker, Wolfram, Reider, Norbert, Bangert, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230957/
https://www.ncbi.nlm.nih.gov/pubmed/32344789
http://dx.doi.org/10.3390/jcm9041241
_version_ 1783535078964461568
author Quint, Tamara
Brunner, Patrick M.
Sinz, Christoph
Steiner, Irene
Ristl, Robin
Vigl, Kornelia
Kimeswenger, Susanne
Neubauer, Katharina
Pirkhammer, Detlev
Zikeli, Martin
Hoetzenecker, Wolfram
Reider, Norbert
Bangert, Christine
author_facet Quint, Tamara
Brunner, Patrick M.
Sinz, Christoph
Steiner, Irene
Ristl, Robin
Vigl, Kornelia
Kimeswenger, Susanne
Neubauer, Katharina
Pirkhammer, Detlev
Zikeli, Martin
Hoetzenecker, Wolfram
Reider, Norbert
Bangert, Christine
author_sort Quint, Tamara
collection PubMed
description Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a real-life clinical setting. Effectiveness and safety outcomes were collected at baseline and after 2, 6, 10, 24, 39, and 52 weeks by using clinical scores for disease activity, as well as serological markers. Ninety-four patients from five dermatological hospitals were included. After 24 weeks of treatment, the median Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI) showed a significant reduction compared to baseline (3.9 ± 0.7 vs. 1.4 ± 0.8 and 26.5 ± 12.5 vs. 6.4 ± 6.5). Interestingly, we observed rosacea-like folliculitis as an unexpected side effect in 6.4% of patients. Dupilumab proves to be an effective and well-tolerated treatment under real-life conditions. The occurrence of rosacea-like folliculitis warrants further mechanistic investigation.
format Online
Article
Text
id pubmed-7230957
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72309572020-05-22 Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis Quint, Tamara Brunner, Patrick M. Sinz, Christoph Steiner, Irene Ristl, Robin Vigl, Kornelia Kimeswenger, Susanne Neubauer, Katharina Pirkhammer, Detlev Zikeli, Martin Hoetzenecker, Wolfram Reider, Norbert Bangert, Christine J Clin Med Article Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a real-life clinical setting. Effectiveness and safety outcomes were collected at baseline and after 2, 6, 10, 24, 39, and 52 weeks by using clinical scores for disease activity, as well as serological markers. Ninety-four patients from five dermatological hospitals were included. After 24 weeks of treatment, the median Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI) showed a significant reduction compared to baseline (3.9 ± 0.7 vs. 1.4 ± 0.8 and 26.5 ± 12.5 vs. 6.4 ± 6.5). Interestingly, we observed rosacea-like folliculitis as an unexpected side effect in 6.4% of patients. Dupilumab proves to be an effective and well-tolerated treatment under real-life conditions. The occurrence of rosacea-like folliculitis warrants further mechanistic investigation. MDPI 2020-04-24 /pmc/articles/PMC7230957/ /pubmed/32344789 http://dx.doi.org/10.3390/jcm9041241 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Quint, Tamara
Brunner, Patrick M.
Sinz, Christoph
Steiner, Irene
Ristl, Robin
Vigl, Kornelia
Kimeswenger, Susanne
Neubauer, Katharina
Pirkhammer, Detlev
Zikeli, Martin
Hoetzenecker, Wolfram
Reider, Norbert
Bangert, Christine
Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis
title Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis
title_full Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis
title_fullStr Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis
title_full_unstemmed Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis
title_short Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis
title_sort dupilumab for the treatment of atopic dermatitis in an austrian cohort-real-life data shows rosacea-like folliculitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230957/
https://www.ncbi.nlm.nih.gov/pubmed/32344789
http://dx.doi.org/10.3390/jcm9041241
work_keys_str_mv AT quinttamara dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis
AT brunnerpatrickm dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis
AT sinzchristoph dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis
AT steinerirene dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis
AT ristlrobin dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis
AT viglkornelia dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis
AT kimeswengersusanne dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis
AT neubauerkatharina dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis
AT pirkhammerdetlev dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis
AT zikelimartin dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis
AT hoetzeneckerwolfram dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis
AT reidernorbert dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis
AT bangertchristine dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis